Sulzer completed the spin-off of medmix in a $340m deal.

Sulzer, a Swiss industrial engineering and manufacturing firm, completed the spin-off of medmix, a provider of high-precision delivery devices in healthcare, in a $340m deal. "APS has grown from a Sulzer start-up to a global leader in precision delivery devices. It is an exciting business with tremendous value creation opportunities. We actively manage our portfolio and always evaluate the opportunity of giving our businesses a future of their own when they reach a level of maturity to thrive standalone, or when we are no longer the best owner. We have reached this moment with APS, which is substantially undervalued as part of Sulzer. The renewed focus of both Sulzer and APS, soon to be medmix, will create significant value for our customers, employees and shareholders," Gregoire Poux-Guillaume, Sulzer CEO.